Plasma Total Testosterone and Incident Cardiovascular Events in Hypertensive Patients
Open Access
- 7 January 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 26 (3) , 373-381
Abstract
Androgen deficiency confers an independent risk for cardiovascular events and total mortality. Hypertension, a major contributory factor to the development of cardiovascular disease, has also been associated with increased prevalence of low testosterone. We investigated whether low androgen concentration predicts incident major adverse cardiovascular events (MACE) in middle-aged nondiabetic hypertensive patients without clinical atherosclerosis. MACE in relation to total testosterone (TT) were analyzed with proportional hazards models in 228 male patients (mean age 56 years). During a mean follow-up of 44 months, 19 of 228 participants (8.3%) experienced a MACE. Compared to patients who did not experience MACE, hypertensive subjects who developed MACE had lower TT concentration (3.9±0.7ng/ml vs. 4.6±1.5ng/ml, P < 0.01) and a higher prevalence of hypogonadism (36% vs. 16%, P < 0.05). Subjects in the lowest TT tertile (4.9ng/ml) in multivariate Cox models adjusted for age, systolic blood pressure, and risk factors (all P < 0.05). A TT plasma level of 5.04ng/ml was associated with a negative predictive value (ability to “rule out” MACE) of 97.2%. Addition of TT to standard risk factors model yielded a net reclassification improvement of 38.8 % (P < 0.05). Our results show that low plasma testosterone is associated with increased risk for a MACE in hypertensive patients. Low endogenous androgen concentration improves risk prediction when added to standard risk factors and may represent a valuable biomarker of prediction of cardiovascular disease risk in these patients.Keywords
This publication has 40 references indexed in Scilit:
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)Diabetes Care, 2011
- Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysisHeart, 2010
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Association of sex hormones and C‐reactive protein levels in menClinical Endocrinology, 2010
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular RiskCirculation, 2010
- Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men StudyEuropean Journal of Endocrinology, 2009
- Testosterone and Blood Pressure RegulationKidney and Blood Pressure Research, 2008
- Cortisol, Testosterone, and Coronary Heart DiseaseCirculation, 2005
- Serum Testosterone Levels and Arterial Blood Pressure in the ElderlyHypertension Research, 2005